Top

Published in:

Open Access 01-12-2016 | Research article

Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate

Authors: Saeid Alinezhad, Riina-Minna Väänänen, Natalia Tong Ochoa, Emily A. Vertosick, Anders Bjartell, Peter J Boström, Pekka Taimen, Kim Pettersson

Published in: BMC Urology | Issue 1/2016

Abstract

Background

The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.

Methods

AMACR and AR mRNA levels were measured with quantitative, reverse-transcription PCR (qRT-PCR) assays in 79 radical prostatectomy (RP) cases (including 69 benign (RP-Be) and 69 cancerous (RP-PCa) samples) and 19 benign prostate samples obtained from cystoprostatectomies. To further determine the detailed areas of altered AMACR expression, AMACR mRNA level measurement and protein staining were performed for three cross-sectioned RP cases.

Results

The median AMACR and AR expression levels were 194.6 (p < 0.0001) and 6.6 (p = 0.0004) times higher in RP-PCa samples than in the benign cystoprostatectomy (CP) samples, respectively. There was no statistically significant difference between RP-PCa and RP-Be samples, except for AMACR/KLK3 (Kallikrein-Related Peptidase 3) ratio, which was significantly higher in RP-PCa samples than in RP-Be samples (p = 0.016). In the systematic study of cross-sections, AMACR mRNA was detected in all of the studied areas including histologically benign tissue, but at significantly higher levels in carcinoma areas (p < 0.001). AMACR protein expression was detected in 80 % (28/35) of the areas that contained carcinoma and in 37 % (44/119) of the benign and PIN areas from the same patients.

Conclusions

AMACR transcripts were detected in all RP-PCa and RP-Be samples but not in non-cancerous CP samples, which suggest a global increase of AMACR expression in cancerous prostates. Therefore patients with false negative biopsies might benefit from an AMACR mRNA measurement when assessing their cancer risk.

Shariat SF, Roehrborn CG. Using biopsy to detect prostate cancer. Rev Urol. 2008;10(4):262–80.PubMedPubMedCentral

de la Taille A, Antiphon P, Salomon L, Cherfan M, Porcher R, Hoznek A, Saint F, Vordos D, Cicco A, Yiou R et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology. 2003;61(6):1181–6.

Ferdinandusse S, Denis S, IJIst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res. 2000;41(11):1890–6.PubMed

Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D Chinnaiyan AM. alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287(13):1662–70.

Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate. 2005;63(4):341–6.CrossRefPubMed

Gologan A, Bastacky S, McHale T, Yu J, Cai C, Monzon-Bordonaba F, Dhir R. Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues. Am J Surg Pathol. 2005;29(11):1435–41.CrossRefPubMed

Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature. 1991;354(6349):159–61.CrossRefPubMedPubMedCentral

Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57(2):314–9.

Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. Survey of gene amplifications during prostate cancer progression by high throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999;59(4):803–6.

10.

Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ,Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220–6.

11.

Neves AF, Araujo TG, Biase WK, Meola J, Alcantara TM, Freitas DG, Goulart LR. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem. 2008;41(14–15):1191–8.

12.

Jiang Z, Wu CL, Woda BA, Dresser K, Xu J, Fanger GR, Yang XJ. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26(9):1169–74.

13.

Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, Grignon DJ, Fanger GR, Amin MB. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12):1588–96.

14.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9(4):401–6.

15.

Vaananen RM, Rissanen M, Kauko O, Junnila S, Vaisanen V, Nurmi J, Pettersson K. Quantitative real-time RT-PCR assay for PCA3. Clin Biochem. 2008;41(1–2):103–8.

16.

Riina-Minna Väänänen, Natalia Tong Ochoa, Peter J Boström, Pekka Taimen, Kim Pettersson. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. BMC Urol. 2015;15:88. doi: 10.1186/s12894-015-0077-7

17.

Nurmi J, Lilja H, Ylikoski A. Time-resolved fluorometry in end-point and real-time PCR quantification of nucleic acids. Luminescence. 2000;15(6):381–8.CrossRefPubMed

18.

Rissanen M, Helo P, Vaananen RM, Wahlroos V, Lilja H, Nurmi M, Pettersson K, Nurmi Jl. Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood. Clin Biochem. 2007;40(1–2):111–8.

19.

Alinezhad S, Vaananen RM, Lehmusvuori A, Karhunen U, Soukka T, Kahkonen E, Taimen P, Alanen K, Pettersson K. Lanthanide chelate complementation and hydrolysis enhanced luminescent chelate in real-time reverse transcription polymerase chain reaction assays for KLK3 transcripts. Anal Biochem. 2014;444:1–7.

20.

Vaananen RM, Lilja H, Cronin A, Kauko L, Rissanen M, Kauko O, Kekki H, Vidback S, Nurmi M, Alanen K et al. Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. \Clin Biochem. 2013;46(7–8):670–4.

21.

Patel AR, Jones JS, Rabets J, DeOreo G, Zippe CD. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology. 2004;63(1):87–9.CrossRefPubMed

22.

Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urology. 2001;166(1):86–91.CrossRef

23.

Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25(11):1397–404.

24.

Kristiansen G. [Immunohistochemical algorithms in prostate diagnostics: what’s new?]. Pathologe. 2009;30 Suppl 2:146–53.CrossRefPubMed

25.

Nickens KP, Ali A, Scoggin T, Tan SH, Ravindranath L, McLeod DG, Dobi A, Tacha D, Sesterhenn IA, Srivastava S et al. Prostate cancer marker panel with single cell sensitivity in urine. Prostate. 2015;75(9):969–75.

26.

Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA et al. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol. 2004;164(3):787–93.

27.

Ouyang B, Leung YK, Wang V, Chung E, Levin L, Bracken B, Cheng L, Ho SM. alpha-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues. Urology. 2011;77(1):249. e241-247.

28.

Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA et all. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68(3):645–9.

29.

Ogden GR, Cowpe JG, Green MW. Evidence of field change in oral cancer. Br J Oral Maxillofac Surg. 1990;28(6):390–2.CrossRefPubMed

30.

Popa I, Fradet Y, Beaudry G, Hovington H, Tetu B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol. 2007;20(11):1121–7.CrossRefPubMed

31.

Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8.CrossRefPubMed

32.

Hockel M, Dornhofer N. The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res. 2005;65(8):2997–3002.PubMed

33.

Yamada H, Tsuzuki T, Maeda N, Yamauchi Y, Yoshida S, Ishida R, Nishikimi T, Yokoi K, Kobayashi H. Alpha methylacyl-CoA racemase (AMACR) in prostate adenocarcinomas from Japanese patients: Is AMACR a “race”-dependent marker? Prostate. 2013;73(1):54–9.

34.

Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol. 2003;27(8):1128–33.CrossRefPubMed

Title: Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate
Authors: Saeid Alinezhad
Riina-Minna Väänänen
Natalia Tong Ochoa
Emily A. Vertosick
Anders Bjartell
Peter J Boström
Pekka Taimen
Kim Pettersson
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Urology / Issue 1/2016
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-016-0128-8

ACC 2024 Congress

Springer Medicine

Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Spontaneous ureteric rupture, a reality or a faux pas?

Case report: Xanthogranulomutous pyelonephritis presenting as “Wilms’ tumor”

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials

Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment

MMP9 overexpression is associated with good surgical outcome in children with UPJO: Preliminary results

Systematic review and meta-analysis of randomised trials of perioperative outcomes comparing robot-assisted versus open radical cystectomy